Ann: Azer-cel Hits Major Milestone in Phase 1b CAR T Trial, page-197

Yes. With what we (IMU) had in the bank already, that was to fund existing & planned trials for the next few years. Until Azer-Cel was known about & (and derisked somewhat in their Ph1a) there was no need for IMU to raise. I for one can accept that this clinical space is fast changing, that the IP is highly complimentary to Oncarlytics & I believe a matter of urgency to acquire that for solid tumour trials, and the added benefit of being Allogenic & progressing well in liquid ie blood cancers.

I believe that management decided that we don’t want to be humped over a barrel, needing to rely on autologous CAR-T to conduct trials for Oncarlytics & be beholden to BP for that.

Maybe that was also a factor in the Merck supply agreement getting cancelled for Her-Vaxx current trial in combo therapy with Keytruda, as in who owns the data? IMU or another KEYNOTE study?

Remember we also have pre-clinical data with Allogenic CAR-T from Celularity (a strategic partnership).

You don’t want to see a deal too early or too late (with patents), but IMU are building all the data in multiple indications, a lot that probably has been ignored by many in the last couple of years ticking all the boxes, including with the FDA.

Just patiently waiting here, but it sure feels like a repeat of 2021 again (pre ASX-200).

Have a lovely weekend folks.